SCHEMBL1747980

SCHEMBL1747980

CC(=N)SCc1ccc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CYP2A6 P11509 1/20 0.50
IDO1 P14902 3/20 0.47
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
PLAU P00749 2/20 0.43
F2 P00734 1/20 0.43
PLG P00747 1/20 0.43
KLKB1 P03952 1/20 0.43
KLK1 P06870 1/20 0.43
PRSS1 P07477 1/20 0.43
SLC11A2 P49281 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
MC4R P32245 1/20 0.41
MC5R P33032 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6634923 0.98 CYP1A2 (0.48) CYP1A2CYP2A6IDO1HTR2AHTR2C
Bromide SCHEMBL1436967 0.98 CYP1A2 (0.48) CYP1A2CYP2A6IDO1HTR2AHTR2C
SCHEMBL13256324 0.82 CYP1A2 (0.43) CYP1A2CYP2A6IDO1HTR2AHTR2C
SCHEMBL20677854 0.82 SLC11A2 (0.65) IDO1SLC11A2TAAR1NOS3NOS1
SCHEMBL6399707 0.82 CYP1A2 (0.50) CYP1A2CYP2A6IDO1HTR2AHTR2C
Bromide SCHEMBL6168962 0.81 CYP1A2 (0.50) CYP1A2CYP2A6IDO1HTR2AHTR2C
Bromide SCHEMBL20677866 0.81 IDO1 (0.65) IDO1SLC11A2TAAR1NOS3NOS1
SCHEMBL3362434 0.79 CYP1A2 (0.47) CYP1A2CYP2A6IDO1PLAUF2
SCHEMBL7875159 0.79 CYP1A2 (0.43) CYP1A2CYP2A6IDO1HTR2AHTR2C
SCHEMBL1140195 0.78 IDO1 (0.61) IDO1SLC11A2TAAR1NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828333-B2 Compounds for the treatment of influenza CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL (DE) 2017-11-28 US disclosed
US-9828333-B2 Compounds for the treatment of influenza CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL (DE) 2017-11-28 US disclosed
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
US-9056110-B2 Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (US) 2015-06-16 US disclosed
US-20140288312-A1 COMPOUNDS FOR THE TREATMENT OF INFLUENZA CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL (DE) 2014-09-25 US disclosed
US-20140288312-A1 COMPOUNDS FOR THE TREATMENT OF INFLUENZA CHRISTIAN-ALBRECHTS-UNIVERSITAT ZU KIEL (DE) 2014-09-25 US disclosed
WO-2013086208-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-13 WO disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS CONFLUENCE LIFE SCIENCES, INC. (US) 2013-06-06 US disclosed
EP-1337510-A2 SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC \"REVERSED AMIDINES\ UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2003-08-27 EP disclosed
US-20030083362-A1 Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ GEORGIA STATE UNIVERSITY 2003-05-01 US disclosed
WO-2002057224-A2 SYNTHESIS AND ANTIMICROBIAL ACTIVITYOF NOVEL DICATIONIC 'REVERSED AMIDINES' UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2002-07-25 WO disclosed
WO-2002055025-A2 COMPOUNDS, METHODS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF BOVINE VIRAL DIARRHEA VIRUS (BVDV) INFECTION AND HEPATITIS C VIRUS (HCV) INFECTION UNIV NORTH CAROLINA (US) 2002-07-18 WO disclosed
EP-1194401-A1 DIACYLHYDRAZINE DERIVATIVES MERCK PATENT GmbH (DE) 2002-04-10 EP disclosed
US-RE37438-E1 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase GLAXO WELLCOME INC. 2001-11-06 US disclosed
WO-2001005753-A1 DIACYLHYDRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2001-01-25 WO disclosed
EP-1028943-A2 ORALLY-ACTIVE NIPECOTAMIDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS Ortho-Mcneil Pharmaceutical, Inc. (US) 2000-08-23 EP disclosed
WO-1999021832-A2 ORALLY-ACTIVE NIPECOTAMIDE GLYCOLAMIDE ESTERS FOR THE TREATMENT OF THROMBOSIS DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 1999-05-06 WO disclosed
US-5866612-A Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase GLAXO WELLCOME INC. (US) 1999-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083362-A1 Synthesis and antimicrobial activity of novel dicationic\"reversed amidines\ HRH4, TLR7, DDAH1 CYP1A2 1407/4885CYP2A6 996/4885IDO1 1608/4885
US-20130143906-A1 SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS MAP3K8, MAP3K1, MAP3K2 CYP1A2 1569/4885CYP2A6 2319/4885IDO1 1725/4885
US-20140288312-A1 COMPOUNDS FOR THE TREATMENT OF INFLUENZA NEU4, NEU3, NEU1 CYP1A2 235/4885CYP2A6 253/4885IDO1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.